Key result
Serum creatinine demonstrated a robust correlation with all motor function metrics (Spearman's ρ ≥ 0.711, p < 0.001), outperforming CCR and CMI as a monitoring biomarker in pediatric SMA.
Why the study?
This study aimed to validate the utility of serum creatinine, creatinine-to-cystatin C ratio, and creatinine muscle index as biomarkers in Chinese pediatric patients with spinal muscular atrophy.
Does serum creatinine correlate with motor function outcomes in pediatric SMA patients undergoing nusinersen treatment?
Cohort (n=21)
No
Does serum creatinine correlate with motor function outcomes in pediatric SMA patients undergoing nusinersen treatment?
Effect estimate: Spearman's ρ ≥ 0.711
p-value: p=<0.001
Routinely measured serum creatinine is a reliable dynamic biomarker for assessing therapeutic response in pediatric SMA patients undergoing nusinersen treatment, outperforming composite indices like CCR and CMI.
May support biomarker monitoring in pediatric SMA but should not alter practice; leaves open confirmation in prospective trials.
Background This study aimed to validate the utility of serum creatinine (Cr), creatinine-to-cystatin C ratio (CCR) and creatinine muscle index (CMI) as biomarkers in Chinese pediatric patients with spinal muscular atrophy (SMA). Methods A retrospective cohort of 21 pediatric patients with 5q-spinal muscular atrophy (5q-SMA) was followed over 18-month after initiating nusinersen therapy. Serum biomarkers (creatinine, cystatin C, and albumin) and multidimensional motor function scores were assessed at six predefined time points. Associations between serum markers and motor function outcomes were analyzed statistically. Results A robust and sustained correlation was identified between Cr levels and all motor function metrics—both at baseline and during follow-up (Spearman’s ρ ≥ 0.711, p < 0.001). This association remained statistically significant even after adjusting for confounders (age, SMA subtype, and albumin levels). In contrast, the baseline relationship between CCR and motor function was attenuated post-adjustment, suggesting confounding effects. CMI exhibited no significant associations in any analysis. Longitudinally, neither Cr nor CCR displayed marked changes over time, whereas CMI declined significantly at the V8 assessment ( p = 0.016). Conclusion Routinely measured Cr is a more reliable dynamic biomarker than CCR and CMI for assessing therapeutic response in pediatric SMA patients undergoing nusinersen treatment.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) conducted a cohort in 5q-spinal muscular atrophy (n=21). Serum creatinine vs. Creatinine-to-cystatin C ratio and creatinine muscle index was evaluated on Correlation between serum biomarkers and motor function outcomes (Spearman's ρ ≥ 0.711, p=<0.001). Serum creatinine demonstrated a robust correlation with all motor function metrics (Spearman's ρ ≥ 0.711, p < 0.001), outperforming CCR and CMI as a monitoring biomarker in pediatric SMA.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: